1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62929B341196BF13785256F64005053E5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/case-studies-in-successful-re-launch-zithromax-and-wellbutrin?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Re-launch

Case Studies in Successful Re-Launch: Zithromax and Wellbutrin

DB Image

ID: 4776


Features:

Metrics, Graphics


Pages/Slides: 23


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"Case Studies in Successful Re-Launch: Zithromax and Wellbutrin"


Study Overview
Successfully re-launching a pharmaceutical product is a difficult feat. However, two well-known pharmaceutical products were able to re-launch into major blockbusters. These case studies, described in detail in a 23-slide presentation, draw on primary and secondary research to illustrate how success was reached. Brand executives can use these case studies to learn how to spot the opportunities, tactics and strategies they need to turn their own re-launched products into major blockbusters.

Key topics

  • Causes for Re-Launch (e.g., initial sales performance, challenges faced)
  • Relaunch Decision Factors
  • Opportunities Seized
  • Pricing Changes
  • Sales Force Changes
  • Overcoming Internal Resistance
  • Specific Relaunch Tactics Used

Key Findings
  • Extensive market research on Zithromax revealed the price was too high. Combined with lowering the price, Pfizer was also able to deploy a different mix of sales people to promote it.
  • Psychiatrists and internal advocates pushed for Wellbutrin's return to the market, and Wellcome (before it was GlaxoWellcome or GSK) was able to establish that few people were at risk for seizures and put forth strong messages highlighting its strengths.

Methodology
This research was gleaned from a larger consulting project for a pharmaceutical client.

Industries Profiled:
Consumer Products; Diagnostic; Pharmaceutical; Medical Device; Biotech; Health Care


Companies Profiled:
Bayer Healthcare; UCB Pharma; Schering-Plough; Roche; Pfizer; Novartis; Merck; AstraZeneca; DSM Pharmaceutical; Sanofi-aventis; Abbott Laboratories; Eli Lilly; GlaxoSmithKline l


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.